Medtronic is sponsoring a series of new clinical tests of its controversial genetically engineered bone-growth product Infuse in an effort to gather long-term data about the optimal dose of the ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) to begin marketing INFUSE® Bone ...

For the first time, U.S. regulators have cleared Medtronic's controversial Infuse Bone Graft biologic product for lower-back surgery for use with plastic — rather than titanium — spinal components.

The Infuse Bone Graft continues to be a pain in the back for Medtronic ($MDT). Health insurer Humana filed a May 30 lawsuit against the device giant for providing ...

DUBLIN and CHICAGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of Infuse™ Bone Graft ...

A U.S. Dept. of Justice probe into Medtronic Inc.’s (NYSE:MDT) marketing practices for its Infuse bone growth product line is growing, according to a report in the New York Times. The Old Grey Lady ...

Medtronic Inc. (NYSE:MDT) faces new heat over the Infuse bone growth product, this time for allegations that the therapy caused excess bone growth in the spinal canal of 70 percent of patients in an ...

WASHINGTONMedical device maker Medtronic Inc. helped write and edit medical journal articles attributed to outside physicians, which downplayed the risks of the company's best-selling bone graft, ...

Medtronic ($MDT) has reached a $22 million settlement with 950 claimants over liability claims related to Infuse Bone Graft. The company denied any wrongdoing and ...

Shareholders sued Fridley-based Medtronic Inc. over claims the medical device company misled investors about the profitability of its Infuse device that stimulates bone growth. The lawsuit, filed ...

Minneapolis-based Medtronic faces approximately 700 lawsuits involving 1,000 patients claiming personal injury due to the company’s Infuse bone graft product, according to the company’s SEC filing for ...